A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorMemorial Sloan Kettering Cancer Center
About this trial
The purpose of this study is to find out whether adding belumosudil to a usual approach for reducing the risk of graft-versus-host disease (GVHD) may be an effective GVHD prevention approach for people with blood cancer who have a stem cell transplant. The investigators will also look at the safety of the study approach.
Eligibility criteria
Qualifiers
Patients ≥ 18 years-old at time of consent.
Diagnosis: hematologic malignancy in morphologic remission who will be treated with RI or NMA conditioning and GVHD prophylaxis CNI-based (CNI without PTCY) plus abatacept or PTCY-based (CNI with PTCY).
Recipients of 7-8/8 related or unrelated HLA-matched or related haploidentical donor.
Peripheral blood stem cell graft
Disqualifiers
Recipient of CD34+ selected or engineered stem cell graft.
Treatment with in vivo T cell depletion (e.g. anti-thymocyte globulin).
Evidence of current uncontrolled cardiovascular conditions, uncontrolled cardiac arrhythmias, symptomatic congestive heart failure, unstable angina, or myocardial infarction within the past 6 months.
Pulmonary dysfunction with DLCO <50% corrected for hemoglobin
Trial design
Treatments tested in this trial
- Belumosudil
Treatment groups
46 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov